|
Q4 FY2024
As of Sep 30, 2024
|
Q3 FY2024
As of Jun 30, 2024
|
Q2 FY2024
As of Mar 31, 2024
|
Q1 FY2024
As of Dec 31, 2023
|
Q4 FY2023
As of Sep 30, 2023
|
Q3 FY2023
As of Jun 30, 2023
|
Q2 FY2023
As of Mar 31, 2023
|
Q1 FY2023
As of Dec 31, 2022
|
Q4 FY2022
As of Sep 30, 2022
|
Q3 FY2022
As of Jun 30, 2022
|
Q2 FY2022
As of Mar 31, 2022
|
Q1 FY2022
As of Dec 31, 2021
|
Q4 FY2021
As of Sep 30, 2021
|
Q2 FY2021
As of Mar 31, 2021
|
Q4 FY2020
As of Sep 30, 2020
|
Q3 FY2021
As of Jun 30, 2021
|
Q1 FY2021
As of Dec 31, 2020
|
Q1 FY2020
As of Dec 31, 2019
|
Q2 FY2020
As of Mar 31, 2020
|
Q3 FY2020
As of Jun 30, 2020
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Assets | ||||||||||||||||||||
| Cash | ||||||||||||||||||||
| Due from Related Parties | ||||||||||||||||||||
| Cash | ||||||||||||||||||||
| Due from Related Parties | ||||||||||||||||||||
| TOTAL ASSETS | ||||||||||||||||||||
| Current Liabilities | ||||||||||||||||||||
| Advanced Receivables | ||||||||||||||||||||
| Accout payable and acrued liabilities | ||||||||||||||||||||
| Advance Receivables | ||||||||||||||||||||
| Account payable Related Parties | ||||||||||||||||||||
| Account payable Others | ||||||||||||||||||||
| Total current Liabilities | ||||||||||||||||||||
| Stockholders' Deficit: | ||||||||||||||||||||
| Common stock, par value $0.001 per share, 75,000,000 shares authorized; 26,420,200 shares issued and outstanding as of September 30, 2024 and 26,320,200 at September 30, 2023 | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Total stockholders' deficit | ||||||||||||||||||||
| Total Liabilities and Stockholder's Equity (Deficit) | ||||||||||||||||||||
| TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT | ||||||||||||||||||||
Loading...
